CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a new anti-angiogenic therapy by targeting PFKFB3, a key regulator of glucose metabolism in endothelial cells. The aim is to create small molecule compounds that inhibit pathological blood vessel growth, addressing significant medical needs in conditions like cancer and inflammation.
Angiogenesis, the growth of new blood vessels, contributes to major pathologies such as blinding ocular disease, inflammation and cancer.
Blocking angiogenesis has therefore become a major field of research and an attractive therapeutic strategy.
Current anti-angiogenic therapies focus on blockade of pro-angiogenic factors, such as VEGF.
However, in cancer, insufficient efficacy, resistance and toxicity restrict the success of anti-VEGF agents.
There is thus an urgent unmet need for novel anti-a…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
